Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA202 Product · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Experimental: IMA202 Product | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated. * Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2 |
| Name | Type | Description |
|---|---|---|
| IMA202 Product | DRUG | The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula. |
| IMADetect® | DEVICE | IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only. |
Inclusion Criteria: * Pathologically confirmed advanced and/or metastatic solid tumor * Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments. * Eastern Cooperative Oncology Gr...
IMA202 Product is an investigational cell therapy being studied for the treatment of solid tumors in adults, including refractory and recurrent cancers. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
IMA202 Product is a TCR-engineered T cell therapy designed to recognize and attack cancer cells. It is being developed by Immatics N.V. (IMTX) as a potential treatment for solid tumors.
IMA202 Product is being developed by Immatics N.V., a biopharmaceutical company listed on the stock exchange under the ticker IMTX.
IMA202 Product is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or any other regulatory agency.
IMA202 Product has one completed Phase 1 clinical trial, NCT03441100, titled 'TCR-engineered T Cells in Solid Tumors: IMA202-101'. This trial enrolled 16 adult patients with solid tumors and was conducted in the United States and Germany.
IMA202 Product is the name used in clinical trial records for the investigational therapy. It is also referred to as IMA202 in the context of the study 'TCR-engineered T Cells in Solid Tumors: IMA202-101'.